Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Current Deferred Revenue (2019 - 2025)

Korro Bio's Current Deferred Revenue history spans 5 years, with the latest figure at $3.3 million for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 51.39% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Sep 2025, up 51.39%, and an annual FY2024 reading of $3.5 million, changed N/A over the prior year.
  • Current Deferred Revenue for Q3 2025 was $3.3 million at Korro Bio, down from $3.9 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $9.4 million in Q1 2021, with the low at $2.2 million in Q3 2024.
  • Average Current Deferred Revenue over 3 years is $4.2 million, with a median of $3.4 million recorded in 2024.
  • Year-over-year, Current Deferred Revenue crashed 75.65% in 2021 and then soared 51.39% in 2025.
  • Tracing KRRO's Current Deferred Revenue over 3 years: stood at $9.4 million in 2021, then tumbled by 62.7% to $3.5 million in 2024, then fell by 5.15% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Current Deferred Revenue are $3.3 million (Q3 2025), $3.9 million (Q2 2025), and $2.8 million (Q1 2025).